Nitroso compounds as nitroxyl donors and methods of use thereof
The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
1. A compound of formula VII:
or a pharmaceutically acceptable salt thereof, wherein
D is selected from alkyl-C(O)—, substituted alkyl-C(O)—, perhaloalkyl-C(O)—, alkenyl -C(O)—, substituted alkenyl-C(O)—, alkynyl-C(O)—, substituted alkynyl-C(O)—, aryl-C (O)—, substituted aryl-C(O)—, heteroaryl-C(O)—, substituted heteroaryl-C(O)—, heterocyclyl-C (O)— and -P(O)(OC 1 -C 8 alky) 2 ;
R 4 is selected from H, substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 2 -C 8 alkenyl, substituted or unsubstituted C 2 -C 8 alkynyl, substituted or unsubstituted acyl, alkoxycarbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, and sulfonyl; and
each R 11a , R 11b , R 12a , R 12b , R 13a , R 13b , R 14a , and R 14b group is independently selected from H, substituted C 1 -C 8 alkyl, unsubstituted C 1 -C 8 alkyl, halo, hydroxyl, alkoxy, cyano, and nitro or two said groups attached to the same carbon atom together with that carbon atom form a carbonyl moiety or two said groups attached to adjacent carbon atoms together with those carbon atoms form a carbon-carbon double bond.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein each R 11a , R 11b ,R 12a , R 12b , R 13a , R 13b , R 14a , and R 14b is independently selected from H and methyl.
3. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R 4 is an unsubstituted C 1 -C 8 alkyl or an acyl moiety.
4. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R 4 is an unsubstituted C 1 -C 4 alkyl, C 1 -C 8 alkyl-C(O)— or aryl-C(O)—.
5. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein R 4 is methyl, CH 3 —C(O)—or phenyl-C(O)—.
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is P(O)(OC 1 —C 8 alkyl) 2 .
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is:
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is of the formula:
9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein D is CH 3 —C(O)—.
10. A pharmaceutical composition comprising (i) a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and (ii) a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10 , wherein the composition is amenable to parenteral administration.
12. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein each R 11a , R 11b , R 12a , R 12b , R 13a , R 13b , R 14a and R 14b is H.
13. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein D is —C(O)CH 3 .
14. The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein R 4 is phenyl-C(O)—.
15. A compound having the formula:
16. A compound having the formula:
17. A compound having the formula: